3 August 2012 - Biopharmaceutical company Endocyte Inc (NasdaqGS:ECYT) said on Thursday that it has received the DOXIL supply to supplement its existing supply to support the ongoing PROCEED trial in ovarian cancer.

Under an agreement, the company received the DOXIL Supply (doxorubicin HCl ...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up